Wolfe Research Initiates Coverage On Avalo Therapeutics with Outperform Rating, Announces Price Target of $48

Benzinga Newsdesk www.benzinga.com Positive 69.1%

Neg 0% Neu 0% Pos 69.1%

Wolfe Research analyst Andy Chen initiates coverage on Avalo Therapeutics (NASDAQ:AVTX) with a Outperform rating and announces Price Target of $48.